NeuroScientific Biopharmaceuticals (ASX:NSB) said that a review of historical studies, data, findings, and publications following the acquisition of Isopogen WA found that StemSmart mesenchymal stromal cell (MSC) therapy showed "promising" results in two early studies in renal transplantation, according to a Wednesday Australian bourse filing.

Isopogen WA is the holder of StemSmart, a patented stem cell technology.

The studies support further clinical development and the potential of StemSmart MSC in both preventing and treating graft failure and rejection, the firm noted.

A case series of 10 adult patients with treatment-refractory acute renal rejection following kidney transplants were treated with StemSmart MSC as a salvage and adjunctive therapy. Eight out of 10 patients retained their kidney following the infusion.

A second study undertaken in 12 adults undergoing deceased-donor renal transplantation showed that StemSmart MSC infusion was well tolerated and safe, and the results were "encouraging" for an improvement in delayed graft function immediately post-transplant.

The firm's shares fell over 3% in recent trading on Wednesday.